GET DAILY SIGNALSChina Pharma Holdings (CPHI): A Closer Look at This China-Focused Pharma Holding Company
Key Takeaways
- CPHI is the ticker for China Pharma Holdings, Inc., a specialty and generic pharmaceutical company listed on the NYSE American.
- The company operates primarily through its Chinese subsidiary, Hainan Helpson Medical and Biotechnology Co., Ltd. ("Helpson"), headquartered in Haikou, Hainan Province, China.
- Its product portfolio spans injectables, tablets, capsules, and oral solutions, including generic drugs and Modern Traditional Chinese Medicines sold mainly on a prescription basis.
- China Pharma Holdings is a small-cap holding company with a limited revenue base, making its financial profile highly sensitive to operating and regulatory conditions in China.
- Investors follow the ticker for its exposure to China's pharmaceutical market, while recognizing notable risks tied to its small size, product concentration, and regulatory environment.
Company Overview
China Pharma Holdings, Inc. (CPHI) develops, manufactures, and markets medicines for human use in the People's Republic of China. The firm functions as a U.S.-incorporated holding company, with operations centered on a wholly owned subsidiary in Hainan Province. This structure gives investors a listed vehicle tied to a specific segment of the Chinese healthcare sector, though it also brings a distinct set of operational and regulatory considerations. From what I see, grasping this setup is essential for understanding both the company's reach and its constraints.
Business Operations and Product Focus
The main operating subsidiary, Helpson, handles development, manufacturing, and marketing of a range of pharmaceutical products. These include dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Therapeutic areas covered span cardiovascular, cerebrovascular, and digestive conditions, along with certain infectious diseases. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The lineup mixes basic generic drugs with Modern Traditional Chinese Medicines, sold mostly through prescription channels in China. Distribution relies on provincial and municipal pharmaceutical logistics firms that serve hospitals and OTC pharmacies. This approach is common among smaller specialty producers in the region and avoids the need for an extensive direct sales team.
As a holding company, China Pharma Holdings depends on its subsidiary for revenue generation and any potential fund transfers. It is based in Haikou, Hainan Province, reports on a calendar-year basis, and falls under the healthcare sector in the specialty and generic drug manufacturing industry.
Investor Interest in CPHI
Investors track CPHI largely for its access to China's sizable and expanding pharmaceutical market. As a China-based manufacturer with a U.S. listing, it offers a publicly traded entry point into a healthcare theme that holds long-term appeal for many. Its emphasis on generics and traditional Chinese medicine provides a narrower focus compared with larger, research-driven global pharmaceutical firms.
The company's positioning centers on established, lower-cost categories rather than new drug development. For those following China's demographic shifts and rising healthcare spending, this small-cap name serves as one way to participate. Its straightforward structure and concentrated portfolio can simplify analysis relative to global peers, though that same concentration heightens certain exposures.
Key Risks to Consider
Several factors warrant attention before looking at CPHI. As a small-cap entity, its financial scale is modest, and limited revenue can magnify the effects of any single product or distribution challenge. Operations are concentrated in China, which brings regulatory, macroeconomic, and policy risks particular to that market, such as shifts in drug pricing or healthcare procurement rules.
Generic pharmaceutical competition remains strong, with pricing pressure potentially squeezing margins. The U.S.-listed holding structure with Chinese operations also involves considerations around cash access from the subsidiary. Like many small-cap issuers, share liquidity and trading volatility tend to be higher than for larger, more established companies.
Using AI Tools in Research
When reviewing names like this, I often turn to Tickeron's AI Screener to apply technical indicators, fundamentals, and industry filters. It helps surface comparable ideas across sectors and supports a more structured review process without replacing individual judgment.
Conclusion
China Pharma Holdings, Inc. holds a focused role in China's specialty and generic pharmaceutical space, producing and distributing injectables, oral medicines, and traditional Chinese medicine products via its operating subsidiary. Its small-cap size, concentrated offerings, and China-centric operations create a distinctive yet higher-risk avenue for exposure to the country's healthcare sector. For investors who weigh both the potential and the regulatory and competitive realities, CPHI stands as a notable example of a cross-listed Chinese pharmaceutical holding company.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for CPHI turns negative, indicating new downward trend
CPHI saw its Momentum Indicator move below the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 109 similar instances where the indicator turned negative. In 102 of the 109 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CPHI turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 42 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CPHI moved below its 50-day moving average on October 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for CPHI moved below the 200-day moving average on October 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CPHI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CPHI entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CPHI's RSI Indicator exited the oversold zone, 30 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 21 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
CPHI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.678) is normal, around the industry mean (6.379). P/E Ratio (-1.357) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.050) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.658) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. CPHI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CPHI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturier of generic and branded pharmaceutical products
Industry PharmaceuticalsGeneric
Advertisement